MEDIVIE_UK_LIMITED - Accounts


Company Registration No. 08189870 (England and Wales)
MEDIVIE UK LIMITED
FORMERLY KNOWN AS OPRO MOTHER & BABY LIMITED
UNAUDITED ABBREVIATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2016
MEDIVIE UK LIMITED
FORMERLY KNOWN AS OPRO MOTHER & BABY LIMITED
CONTENTS
Page
Abbreviated balance sheet
1
Notes to the abbreviated accounts
2 - 3
MEDIVIE UK LIMITED
FORMERLY KNOWN AS OPRO MOTHER & BABY LIMITED
ABBREVIATED BALANCE SHEET
AS AT
31 MARCH 2016
31 March 2016
- 1 -
2016
2015
Notes
£
£
£
£
Fixed assets
Intangible assets
2
-
0
985
Tangible assets
2
130
522
Investments
2
163,908
-
0
164,038
1,507
Current assets
Debtors
11
1,323
Cash at bank and in hand
280
604
291
1,927
Creditors: amounts falling due within one year
(425,668)
(220,438)
Net current liabilities
(425,377)
(218,511)
Total assets less current liabilities
(261,339)
(217,004)
Capital and reserves
Called up share capital
3
1,600
1,600
Share premium account
152,178
152,178
Other reserves
161,133
161,133
Profit and loss account
(576,250)
(531,915)
Shareholders'  funds
(261,339)
(217,004)
For the financial year ended 31 March 2016 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
-
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These abbreviated financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.
Approved by the Board for issue on 30 January 2017
Mr J  Rurka
Director
Company Registration No. 08189870
MEDIVIE UK LIMITED
FORMERLY KNOWN AS OPRO MOTHER & BABY LIMITED
NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 31 MARCH 2016
- 2 -
1
Accounting policies
1.1
Accounting convention

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The validity of the assumption depends upon the continued financial support of the parent company.

If the company were unable to continue in existence for the foreseeable future, adjustments would have to be made to reduce the balance sheet values of assets to their recoverable amounts and to provide for any further liabilities that might arise.
1.2
Compliance with accounting standards
The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), which have been applied consistently (except as otherwise stated).
1.3
Turnover

Turnover represents amounts receivable for royalty fees for grant of license for the use of IP to produce, further development and sell, and market products worldwide. royalty fees for grant of license for the use of IP to produce, further development and sell, and market products worldwide.

1.4
Research and development
Development costs is written off in equal annual instalments over its estimated useful economic life.
1.5
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:
Computer equipment
33.33% straight line
1.6
Investments
Fixed asset investments are stated at cost less provision for diminution in value.
1.7
Foreign currency translation
Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.
MEDIVIE UK LIMITED
FORMERLY KNOWN AS OPRO MOTHER & BABY LIMITED
NOTES TO THE ABBREVIATED ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016
- 3 -
2
Fixed assets
Intangible assets
Tangible assets
Investments
Total
£
£
£
£
Cost
At 1 April 2015
3,225
1,175
-
4,400
Additions
-
-
163,908
163,908
At 31 March 2016
3,225
1,175
163,908
168,308
Depreciation
At 1 April 2015
2,240
653
-
2,893
Charge for the year
985
392
-
1,377
At 31 March 2016
3,225
1,045
-
4,270
Net book value
At 31 March 2016
-
130
163,908
164,038
At 31 March 2015
985
522
-
0
1,507
Holdings of more than 20%
The company holds more than 20% of the share capital of the following companies:
Company
Country of registration or
Shares held
incorporation
Class
%
Subsidiary undertakings
Medivie USA Inc.
USA
Ordinary
90.00
The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows:
Capital and reserves
Profit/(loss) for the year
2016
2016
Principal activity
£
£
Medivie USA Inc.
Commercialising the licensed products in Canada and the USA
177,399
(1,397)
3
Share capital
2016
2015
£
£
Allotted, called up and fully paid
1,600 Ordinary of £1 each
1,600
1,600
2016-03-312015-04-01falsetruetruetruetruetruetmpE46E.html2017-01-31081898702015-04-012016-03-31081898702016-03-31081898702015-03-31081898702015-03-3108189870uk-bus:Director12015-04-012016-03-3108189870uk-gaap:ComputerEquipment2015-04-012016-03-3108189870uk-gaap:Subsidiary12015-04-012016-03-3108189870uk-gaap:Subsidiary12016-03-3108189870uk-bus:OrdinaryShareClass12015-04-012016-03-3108189870uk-bus:OrdinaryShareClass12016-03-3108189870uk-bus:OrdinaryShareClass12015-03-31xbrli:purexbrli:sharesiso4217:GBP